December 3, 2018
Toronto, December 3, 2018 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10 percent the industry committed to when their periods of market exclusivity were first increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).
November 22, 2018
Toronto – November 22, 2018 – Biosimilars Canada, the national association representing Canada’s biosimilar medicines industry, today announced that Innomar Strategies, Canada's leading specialty pharmaceuticals service provider has been selected as the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform. The platform will provide a common suite of PSP services for Biosimilars Canada members going forward that can be customized to meet the individual needs of the therapy, the biosimilar sponsor and payers.
October 2, 2018
CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION CONGRATULATES FRANÇOIS LEGAULT AND THE COALITION AVENIR QUÉBEC FOR THEIR ELECTION VICTORY
Montréal, October 2, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the election of François Legault and the Coalition Avenir Québec in Quebec on Monday :
October 1, 2018
Toronto, October 1, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA):
September 24, 2018
New Poll: Canadians Strongly Agree that Access to Affordable Prescription Medicines is Most Important Priority for NAFTA 2.0
Toronto, September 24, 2018 – A new poll confirms that Canadians do not want their access to generic and biosimilar medicines traded away under a new NAFTA deal.
September 20, 2018
September 6, 2018 The Honourable Chrystia Freeland Minister of Foreign Affairs 125 Sussex Drive Ottawa, Ontario K1A 0G2 Re: Access to Affordable Medicines and NAFTA
September 19, 2018
The intellectual-property provisions included in the final agreement could delay when cost-saving generic and biosimilar medicines can enter the Canadian market, writes the president of the Canadian Generic Pharmaceutical Association.
September 5, 2018
Toronto, September 5, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the resumption of trade negotiations between the United States and Canada:
August 28, 2018
Toronto, August 28, 2018 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the preliminary agreement-in-principle announced August 27, 2018 between the United States and Mexico:
April 9, 2018
The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Mr. Peter Hardwick, Chief Commercial Officer and Executive Vice President of Apotex, as Chair of CGPA.
January 29, 2018
A Joint Statement from the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association
On behalf of participating federal, provincial, and territorial public drug plans, the pan-Canadian Pharmaceutical Alliance (pCPA), with the Canadian Generic Pharmaceutical Association (CGPA) have jointly developed a new five-year initiative that will provide significant savings for all Canadians who use prescription generic drugs, participating public drug plans, and employee drug plans.